Elimination of meropenem by continuous hemo(dia) filtration: An in vitro one-compartment model

International Journal of Artificial Organs

Volumn 22, Issue 5, 1999, Pages 307-312

  Schroeder, Torsten H ^a,b   Krueger, W A ^a   Hansen, M ^a   Hoffmann, E ^a   Dieterich, H J ^a   Unertl, K ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Hemodiafiltration; Hemofiltration; Meropenem; Pharmacokinetics

Indexed keywords

BACTERIA;

CARBAPENEM ANTIBIOTIC; DIALYSATES; FILTER MATERIALS; HEMODIAFILTRATION; HEMOFILTRATION; IN-VITRO; MEROPENEM; ONE COMPARTMENT MODELS; RENAL REPLACEMENT THERAPIES; SURFACE AREA;

FLOW RATE;

MEROPENEM; POLYAMIDE; POLYSULFONE;

ACUTE KIDNEY FAILURE; ANTIBIOTIC THERAPY; ARTICLE; CALCULATION; DIALYSATE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; FLOW RATE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEMODIALYSIS; HEMOFILTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY INFECTION;

EID: 0032810691     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139889902200503     Document Type: Article

References (22)

1. Edwards JR. Meropenem: A microbiological overview. J Antimicrob Chemother 1995; 36, (Suppl. A): S1-17.
2. Mehtar S, Dewar EP Leaper DJ, et al. A multi-centre study to compare meropenem and cefotaxime and metronidazole in the treatment of hospitalized patients with serious infections. J Antimicrob Chemother 1997; 39: 631-8.
3. Sieger B, Jon Berman S, Geckler RW et al. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: A randomized study. Crit Care Med 1997; 25: 1663-70.
4. Mouton YJ, Beuscart C and the meropenem study group. Empirical monotherapy with meropenem in serious bacterial infections. J Antimicrob Chemother 1995; 36, Suppl. A: 145-56.
5. Mouton JW, van den Anker JN. Meropenem clinical pharmacokinetics. Clin Pharmacother 1995; 28: 275-86.
6. Drusano D, Hutchison M. The pharmacokinetics of meropenem. Scand J Infect Dis 1995; 96: 11-6.
7. Bedikian A, Okamoto MP, Nakahiro RK et al. Pharmacokinetics of meropenem in patients with intra-abdominal infections. Antimicrob Agents Chemother 1994; 38: 151-54.
8. Bax RP, Bastain W, Featherstone A, Wilkinson DM, Hutchison M, Haworth SJ. The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother 1989; 24 (Suppl. A): 311-20.
9. Christensson BA, Nilsson-Ehle I, Hutchison M, Haworth SJ, Öqvist B, Norrby SR. Pharmacokinetics of meropenem in subjects various degrees of renal impairment. Antimicrob Agents Chemother 1992; 36: 1532-37.
10. Chimata M, Nagase M, Suzuki Y, Shimomura M, Kakuta S. Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease. Antimicrob Agents Chemother 1993; 37: 229-33.
11. Leroy A, Fillastre JP, Borsa-Lebas F, Etienne I, Humbert G. Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment. Antimicrob Agents Chemother 1992; 36: 2794-8.
12. Krueger WA, Schroeder TH, Hutchison M et al. Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration. Antimicrob Agents Chemother 1998; 42: 2421-4.
13. Thalhammer F, Schenk P, Burgmann H et al. Single-Dose Pharmacokinetics of meropenem during continuous venovenous hemofiltration. Antimicrob Agents Chemother 1998; 42: 2417-20.
14. Giles LJ, Barber AC, Creed G, Ng B, Beale RJ, McLuckie A. Pharmacokinetics of meropenem in intensive care patients receiving continuous renal replacement therapy. In: 18th International Symposium of Intensive Care and Emergency Medicine. Abstracts of Posters. 1998; P130: 65.
15. Cotterill S. Antimicrobial prescribing in patients on hemofiltration. J Antimicrob Chemother 1995; 36: 773-80.
16. Davies JG, Kingswood JC, Sharpstone P, Street MK. Drug removal in continuous haemofiltration and hemodialysis. Br J Hosp Med 1995; 45: 524-8.
17. Bressolle F, Kinowski JM, de la Coussaye JE, Wynn N, Eledjam JJ, Galtier M. Clinical pharmacokinetics during continuous haemofiltration. Clin Pharmacokinet 1994; 26: 457-71.
18. Reetze-Bonorden P, Böhler J, Keller E. Drug dosage in patients during continuous renal replacement therapy. Clin Pharmacokinet 1993; 24: 362-79.
19. Burman LA, Nilsson-Ehle I, Hutchison M, Haworth SJ, Norrby SR. Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem. J Antimicrob Chemother 1991; 27: 219-24.
20. Kronfol NO, Lau AH, Barakat MM. Aminoglycoside binding to polyacrylonitrile hemofilter membranes during continuous hemofiltration. Trans Am Soc Artif Intern Organs 1987; 33: 300-4.
21. Lau AH, Kronfol NO. Determinants of drug removal by continuous hemofiltration. Int J Artif Organs 1994; 17: 373-8.
22. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22: 89-96.